• PMA changes p53, p21 and cyclin D1 levels.
Introduction
PKC was discovered in 1977 [12] in studies using rat brain extracts. This enzyme is a member of the serine/threonine phosphotransferases family and is divided into three subfamilies: conventional (␣, ␤I, ␤II and ␥), novel (␦, , and ) and atypical ( and ). The PKC isoenzymes activate different intracellular cell signaling pathways [10] involved in many biological processes such as cell proliferation and differentiation, neural plasticity, immunity and cell death [27] . It was also observed that PKC can limit the proliferation of certain cancer cell lineages [17, 33] .
PMA is a phorbol ester isolated from the seed oil of Croton tiglium and other plants of the Euphorbiaceae family [3] . It is an activator of the conventional and novel PKC classes. It is well known that the PMA tumor-promoter activity is associated with sustained activation of PKC, compared with that of the physiological activator diacylglycerol [22] . However, in other systems, PMA treatment decreases cell proliferation, both during normal development and in cancer cell lines. This effect is attributed to PKC's ability to modulate the expression of transcription factors and cell cycle regulatory proteins [3, 9, 33] .
The balance between cell proliferation and differentiation is regulated by a mechanism that involves the cell cycle control. One important way to influence this balance is by changing the expression of key regulatory proteins of the cell cycle (cyclins, cyclin-dependent kinases and inhibitors of cyclin-dependent kinases) through transcription alteration and also by turnover modification. During the development of the nervous system, cells undergo a period of intense proliferation where cyclins and cyclin-dependent kinases regulate cell cycle progression. At the appropriate time, specific cell signaling pathways interfere with the expression and activity of these proteins inhibiting cell cycle progression through a pause on the G1 phase. The cells enter then in the quiescent G0 phase where the differentiation process takes place [34] .
It has been demonstrated in various regions of the nervous system that PKC is able to mediate the release of neurotransmitters (as acetylcholine) [16, 38] . Acetylcholine is widely distributed throughout the central nervous system [2] and plays a critical role in cerebral cortical development, cortical activity, cerebral blood flow control, sleep-wake cycle as well as in modulating cognitive performances [31] . The muscarinic acetylcholine receptors (mAChR) are divided in five subtypes (M1-M5). Members of the "M1-like" family (M1, M3, and M5) are associated with the Gq protein and phosphatidylinositol turnover. In contrast, members of the "M2-like" family (M2 and M4) are generally linked to inhibition of adenylyl cyclase activity [18] .
We previously showed that PMA treatment for 48 h decreases retinal cells proliferation in culture, an effect mediated mAChR activation and polypeptide release [29] . We also demonstrated that PMA treatment decreases M1 receptor expression, and that this effect mimics the decrease that occurs during the normal development of retinal tissue [30] . Based on these previous results, in this work we analyzed the levels of three important regulatory proteins of the cell cycle p53, p21 and cyclin D1, as well as the levels of M3 receptor following PMA treatment of retinal cell cultures. We also investigated the levels of M3 receptor and p21 during the postnatal development of retinal cells.
Materials and methods

Chemicals
Medium 199 and fetal calf serum were purchased from Gibco (USA). PMA, rabbit anti-M3 antibody, poly-l-ornithine, lglutamine, penicillin and streptomycin sulfate were obtained from Sigma (USA). Trypsin was purchased from Worthington (USA). Culture dishes were obtained from TPP (Switzerland). Hyperfilm, acrylamide, methylene bis acrylamide, 2-mercaptoethanol, secondary antibody anti-rabbit HRP-linked, ECL Western blot detection kit, PVDF membrane and [methyl-3 H]-thymidine were obtained from Amersham (USA). Sodium dodecyl sulfate, Tris (Tris[hydroxymethyl]aminomethane) and ammonium persulfate, were purchased from USB (USA). Glycine was obtained from Queel (Brazil). Tween 20, comassie blue, trichloroacetic acid (TCA) and glycerol were obtained by VETEC (Brazil). Rabbit anti-cyclin D1 was obtained from Cell Signaling Technology (USA). Secondary rabbit anti-goat HRP linked, goat anti-actin (C-11) antibody, rabbit anti-p53 antibody and bovine serum albumin (BSA) and rabbit anti-p21 antibody were obtained from Santa Cruz Biotechnology (USA). TEMED and molecular weight standard were obtained from Invitrogen (USA). Methanol was obtained from J.T. Baker (USA).
Retinal cultures
Cultures containing neurons, glial cells and mostly neuroblasts were prepared using techniques previously described [28] . Postnatal Lister Hooded rats (P0-P2) were used.
Cells were placed on Petri dishes previously treated with polyl-ornithine (25 g/mL) at a plating density of 10 5 cells/cm 2 . The cultures were maintained in a humidified atmosphere of 5% CO 2 and 95% air at 37 • C for 48 h. All procedures using animals were approved by the local committee for animal care and experimentation (CEPA-projects #00196-10). All efforts were made to minimize the number of experimental animals and their suffering.
Western blot
The levels of M3 receptors, p53, cyclin D1, p21 and actin were determined [30] . Actin was used as a loading control protein.
Membranes were incubated with rabbit anti-M3 antibody (0.8 g/ml), anti-p53 antibody (1:200), anti-cyclin D1 antibody (1:1000), anti-p21 antibody (1:500) or goat anti-actin (C-11) antibody (1:500). Membranes were washed in TBS and then exposed to HRP-conjugated secondary anti-rabbit (1:10,000) or anti-goat IgG antibody (1:5000) at room temperature for 60 min. Detection was performed on X-ray film (hyperfilm) using chemiluminescence system (ECL). The density of protein bands was analyzed by densitometry with Scion Image. The mean value for the control was set at 100%.
[ 3 H]-thymidine incorporation
Retinal explants (P0-P14) were incubated in medium without serum in the presence of 1 Ci/mL of [methyl-3 H]-thymidine and maintained in a shaker at 60-70 rpm for 60 min at 37 • C, in atmosphere of 95% air and 5% CO 2 . Then explants were washed three times with medium without serum to remove the [methyl-3 H]-thymidine not incorporated. Following, the medium was removed and 200 L of 1 N NaOH were added to each sample and maintained for 15 min. Subsequently, 3 mL of MilliQ water and 600 L of 50% TCA were added. After 30 min each sample was filtered in Whatman GF/B filters under negative pressure. The filters were placed at 100 • C for 30 min to dry. The radioactivity was then determined by liquid scintillation.
Statistical analysis
The overall statistical analysis was first obtained by one-way analysis of variance (ANOVA). Statistical significance of all pairs of multiple groups of data was assessed by Newman-Keuls comparison test. To analyze two experimental groups we used Student's t-test. A P value <0.05 was considered statistically significant.
Results
PMA effect on the levels of p21, p53 and cyclin D1
To understand the mechanism involved in the anti-proliferative effect of PMA on retinal cells we evaluated its influence on the levels of three important proteins involved in the regulation of the transition of G1 to S phases of cell cycle: p21, p53 and cyclin D1 [14, 42] . Fig. 1 shows that PMA treatment of retinal cell cultures for 48 h produces an increase (28% compared to the control) in p21 levels (Fig. 1A, B) and an increase in p53 levels (57% compared to the control) (Fig. 1C, D) . Following, we investigate the effect of PMA on the expression of cyclin D1. Our data show that retinal cells treated with PMA 50 ng/mL exhibit a 54% decrease in cyclin D1 levels (Fig. 1E, F) .
Retinal tissue: proliferation pattern and p21 levels
When we investigated the levels of p21 during the normal postnatal development of retinal tissue (P0-P30), we observed a gradual increase in p21 levels up to P7, when it reaches a 57% increase compared to P0. In P14, p21 levels decreases returning to P0 levels. These levels were maintained until P30 ( Fig. 2A, B) . We also evaluated the proliferation pattern of retinal tissue during the postnatal days 0-14. Fig. 2C shows that there is a dramatic decrease in retinal cells proliferation in P7 and P14, when it is well known that the tissue achieved its mature developmental phenotype [4, 39] . During the developmental postnatal stages the cellular populations of the retinas changes gradually. The neuroblast cells differentiate into neurons and glial cells present in the mature tissue [19] .
M3 receptors levels in normal retinal development and in culture cells treated with PMA
Our previous results demonstrated that the decrease in cell proliferation mediated by PMA treatment is dependent on muscarinic receptor activation, and also that it induces a significant decrease in M1 receptors levels [29, 30] . As literature shows that M3 receptors are involved in the process of cell differentiation [13, 20] , we analyze if PMA treatment is also interfering the levels of the M3 acetylcholine receptor type. We first analyzed the levels of M3 receptors in retinal cell cultures treated with PMA for 48Hs. Fig. 3A and B show that 50 ng/mL PMA treatment induces a 102% increase in the M3 receptor levels. Following, we evaluated the expression of M3 receptors during normal development of postnatal retinal tissue, using rat retinal tissue on postnatal days 0, 4, 7, 14 and 30 (P0-P30). 
Discussion
The regulation of the transition of G1 to S phases of the cell cycle is the goal of different signaling cascades triggered by extracellular signals that influences cell proliferation, including PKC activation [6] . p53 is a transcription factor that negatively regulates the cell cycle by induction of p21, a cdk inhibitor. p21 leads to the inhibition of the complex cyclinD/cdk4/6, that regulates G1/S phase transition [14] . It was demonstrated that DNA damage activates the transcription of p21 in a p53-dependent pathway [11] . We showed that PMA treatment exerts the effect of decreasing cell proliferation of retinal cells by changing p21, p53 and cyclin D1 levels. Literature shows that p53 can be phosphorylated by PKC [6] and that p53 phosphorylation is important for its DNA binding activity [15, 25, 37] . Corroborating our results, it was observed in human endometrial cancer cells that treatment with growth hormonereleasing hormone antagonist induces an increase in p53 and p21 expressions via PKC activation [41] . Literature demonstrates that PKC␦ activation is able to induce p53 accumulation [1, 23] . In human hepatoma cells PMA induced a transient increase p53 expression, observed from 30 min of incubation until 180 min, and a posterior fall in p53 expression observed after 6 h of incubation [32] . However, it is also described the regulation of p21 expression by a p53 independent mechanism, and, indeed, PMA effect on cell growth inhibition can also be mediated by this mechanism [24, 36] . We believe that PMA can induce G1 arrest through different mechanisms depending on cell type and possibly by the developmental stage. It could be explained by the presence of different PKC isoforms in the same cell, by the complexity of the signaling pathways that can be triggered and also by the changes in isoforms expression according to the developmental stage. Indeed, it was demonstrated in yeast that PKC activation can induce both positive and negative influence on p53 depending on the PKC isoform activated [7] .
Although PMA induces PKC downregulation, in our previous work [29] we demonstrated that the anti-proliferative effect of PMA is dependent on PKC activation. Literature shows the expression of different PKC isoenzymes in retinal tissue. It was demonstrated PKC␣, ␤, and in bipolar cells, PKC␦ in Müller cells, PKC in the inner segments of photoreceptor and PKC / in horizontal cells [40] . Our next step will be to identify the PKC isotype involved in the PMA effect.
Cyclin D1 forms a complex with CDK4/6 leading to phosphorylation and subsequent inactivation of the retinoblastoma protein (pRb). The Rb inactivation increases cell proliferation because it promotes the release of E2F, a transcription factor that has a role on the progression of the G1 to S phase [35, 42] . Literature demonstrated that the decrease in cyclin D1 levels induces an increase in the duration of G1 phase, a reduction in proliferation and a loss of carcinogenicity in nude mice [5] . The decrease in cyclin D1 levels induced by PMA treatment is in accordance to the anti-proliferative effect observed with this treatment.
Analyzing our results we conclude that the anti-proliferative effect of PMA in cultured retinal cells of newborn rats is exerted by a signaling pathway initiated by PKC activation that interferes in cell cycle progression by a mechanism that involves the change in p21, p53 and cyclin D1 levels. Meng and collaborators also demonstrated that tetrandrine, an antitumor alkaloid, exerts its effect on inhibiting the proliferation of human colon carcinoma cells by increasing p53 and p21 and decreasing cyclin D1 levels, leading to the inhibition of the progression of G1 phase [21] . It was also demonstrated that PMA treatment of lung cancer cells induces cell growth arrest by a mechanism that involves an increase in p21 levels [33] .
Our results show that the levels of p21 increases from P0 to P7, concomitant with the differentiation process of retinal tissue, and we observe the falling in p21 levels from P7 to P14, exactly when the decrease in retinal tissue proliferation occurs. It is interesting to note that the 48 h PMA treatment is mimicking this same pattern in retinal cells culture. This fact corroborates to our hypothesis that PMA is stimulating the differentiation of retinal cells.
As our previous work demonstrated that muscarinic receptor activation is an essential step on the anti-proliferative PMA effect and that it induces a decrease in M1 receptor levels [29, 30] , we supposed that PMA treatment could be inducing a change in the balance between acetylcholine receptor subtypes levels. The present work demonstrates that the chronic activation of PKC by PMA triggers a significant and opposite effect on the expression of M1 and M3 receptors subtypes, as it induces an increase in M3 receptor levels that contrasts with the decrease in M1 receptor previously observed [30] . It is interesting to note that the PMA effect on the levels of M1 and M3 mimics the changes in the levels of these receptors that occur during normal development accelerating the muscarinic M1 and M3 receptors pattern change that normally occurs during tissue maturation.
Muscarinic receptors activation is involved in aspects concerning neuronal differentiation and also that there is a change in the subtypes expression during tissue development. Data from literature showed that carbachol, an acetylcholine analog, produces neurite outgrowth in hippocampal neurons by activating M3 receptors in astrocytes [13] . Muscarinic receptors are also present in glial cells. It was seen that oligodendrocyte cell cultures express all muscarinic receptor subtypes being M3 representing the highest level both in progenitor and mature oligodendrocytes. They also observed that in mature oligodendrocytes there was a decrease in the expression of M1, M3 and M4 immunoreativities [8, 26] . In chick retina, it was observed an increase in M3 receptor expression later in the development [20] . These data are in accordance with our findings of the change in muscarinic receptor subtypes levels during tissue development.
In conclusion, our results demonstrate that PMA treatment induces a modulation of the phenomenon of proliferation/differentiation of rat retinal cells in culture by controlling the levels of p21, in a p53 dependent manner. It also promotes a change in the balance between M1 and M3 receptors levels mimicking the pattern observed in the mature tissue.
